Integration of MC38 tumor‐specific neoantigens into C‐NMC38 (GNNAFRVYLMLPLSERP)‐LNPs‐vaxD18 resulted in significant suppression of MC38 tumor progression compared to Mix‐vax‐treated groups (Figure 7F). This evidence concerns the gene MIXL1 and neoplasm.